Waters 2025 LC Symposium - Day 2 - GLP-1 Analog Development: Purification, Characterization, Release Testing
Waters 2025 LC Symposium
Waters 2025 LC Symposium – LC Solutions for Emerging Therapeutics
Overview
Liquid chromatography plays a critical role in ensuring the safety of emerging therapeutics such as PROTACs, cell and gene therapies, and GLP-1 drug products. Join this free symposium to gain insights from forward-thinking global leaders in LC technology. You will learn about the latest advancements addressing analytical and purification challenges posed by these transformative therapeutics.
Learning objectives
- Learn how our experts are handling unique analytical challenges in emerging therapeutics
- Explore advanced LC technologies applied to critical issues in PROTACs, cell and gene therapies, and GLP-1 drugs
- Pose your questions to our expert panel on your analytical challenges with emerging therapeutics
Who should attend
- LC scientists, managers and directors from the pharmaceutical industry
Day 2: Purification and QC Release of GLP-1 Analogs: From Characterization to Final Approval
As peptide-based drugs like liraglutide, semaglutide, and tirzepatide gain prominence in treating type 2 diabetes and supporting weight management, ensuring their purity is more critical than ever. This session explores the essential role of chromatography in the purification, impurity profiling, and release testing of these complex therapeutics.
Experts from Neopharm Labs and Waters Corporation will share real-world case studies on peptide purification and impurity analysis using advanced LC technologies. The session will also highlight how Waters’ hyphenated LC-UV/MS workflows can streamline impurity identification, reduce analytical workload, and accelerate development timelines.
Ideal for scientists involved in peptide drug development, this session offers practical insights into modern purification strategies and analytical tools that support the successful development and release of GLP-1 analogs.
Presenter: Michael R. Miller (Principal Scientist, Neopharm Boston)
Michael has worked at Neopharm Boston for 4 years and has over 10 years of chromatographic and mass spectrometric experience. At SUNY University at Albany, he studied RNA Biochemistry and LC-MS/MS analysis of large RNAs. Joining Neopharm Boston in 2021 as an Analytical Scientist, Michael spent two years performing HPLC and SFC separations at analytical and preparative scale. Moving up to Lab Supervisor and ultimately Principal Scientist he using his large molecule knowledge to bring Neopharm Boston into the large molecule space.
Presenter: Duanduan Han, Ph.D. (Senior Scientist, Waters Corporation)
Duanduan joined Waters in 2021. Her work has focused on LC/MS method development and troubleshooting, impurity profiling, raw material screening of GLP-1, lipid nanoparticle, surfactant, oligonucleotide, mAb, and other biologic drug products. She received her PhD of chemical engineering from the Texas A&M University.
Moderator: Arjan Timmerman (Pharma Market Development Manager EMEA, Waters Corporation)
Arjan Timmerman is a market development manager at Waters working in EMEA. Prior to joining Waters in 2014 he worked for 17 years as an Analytical Scientist in the Small Molecule Pharmaceutical industry in various Chemical and Pharmaceutical late-stage development labs.
Since 2023 he became QA/QC market development manager for EMEA working in a dedicated team and focuses on Pharmaceutical workflows, AQbD, Impurities, LC Chromatography and Compliance.
